Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | completed | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03093922 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT03643510 | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | completed | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04489771 | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | completed | Phase 2 | 154 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Sep 24, 2026 | clinicaltrials |
| NCT03425565 | A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer(PEACOCC) | completed | Phase 2 | 48 | University College, LondonOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04335682 | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide(ARACOG) | completed | Phase 2 | 111 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04053842 | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy(IGPC-5) | completed | Phase 2 | 16 | Glenn BaumanOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05021237 | Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer | completed | Phase 2 | 12 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05670106 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03042468 | Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | completed | Phase 1 / Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05634499 | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer(EndomERA) | completed | Phase 2 | 33 | Hoffmann-La RocheINDUSTRY | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | completed | Phase 2 | 63 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 14, 2026 | clinicaltrials |
| NCT01807065 | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | completed | Phase 2 | 51 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03315754 | Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. | completed | Phase 2 | 50 | Steba Biotech S.A.OTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05877820 | A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | completed | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02675829 | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | completed | Phase 2 | 131 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01261728 | Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 35 | Inovio PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02880007 | Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer(TRIDICOL) | completed | Phase 2 | 48 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04090710 | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer(CYTOSHRINK) | completed | Phase 2 | 66 | Ontario Clinical Oncology Group (OCOG)OTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04558866 | Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)(ExBAT) | completed | Phase 2 | 51 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05348356 | Nirogacestat in Ovarian Granulosa Cell Tumors | completed | Phase 2 | 53 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05979298 | Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 2 | 40 | CureLab OncologyINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06395753 | A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | completed | Phase 2 | 55 | Debiopharm International SAINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT03188432 | Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | completed | Phase 2 | 31 | CatalYm GmbHINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06907641 | Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy(Co-PSMA) | completed | Phase 2 | 50 | St Vincent's Hospital, SydneyOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03495882 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | completed | Phase 1 / Phase 2 | 175 | Agenus Inc.INDUSTRY | 9 | Aug 11, 2026 | clinicaltrials |
| NCT03587662 | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05478239 | ArtemiCoffee in Patients With Rising PSA | completed | Phase 2 | 20 | Zin W MyintOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04415944 | Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | completed | Phase 2 | 10 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03026062 | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 260 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT01797523 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03606837 | 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging(PROSTATEP) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03796767 | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer(SOAR) | completed | Phase 2 | 20 | University of UtahOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05512377 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT04743934 | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer(RAD 2003) | completed | Phase 2 | 44 | Andrew McDonaldOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | completed | Phase 2 | 14 | Thomas Jefferson UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03716739 | Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | completed | Phase 2 | 136 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials